Mr. Baharaff is the co-founder of Galmed Pharmaceuticals Ltd., and has served as CEO since 2012, and President as of 2015. Since its inception in 2000, Mr. Baharaff served as CFO since 2000. He holds a Bachelor of Science degree from the University of London (LSE) and LLB and MA degrees from Cambridge University. Mr. Baharaff has held a number of directorships including a SVP position at Isramex Projects Ltd., and T+M Trusteeship & Management. He also serves as a Director of the Tel-Aviv Museum of Arts, chairing the committee for educational activities.
Dr. Hayardeny joined Galmed in September 2016 bringing more than 16 years of experience in drug development as part of Teva Pharmaceuticals’ global R&D Division. Prior to joining Galmed, Dr. Hayardeny served as Teva’s Senior Director and Head of Research Scientific Affairs. In that capacity, Dr. Hayardeny established the scientific positioning of Teva’s innovative compounds. Additionally, Dr. Hayardeny was responsible for the company’s relationship with institutions of higher education; managing Teva’s global research collaborations and publications. Dr. Hayardeny holds a Ph.D. from Sackler School of Medicine and an MBA from Recanati Business School at Tel Aviv University.
Professor Ran Oren, MD, joined Galmed as Chief Medical Officer in mid-2016. Dr. Ran Oren is a Professor of Gastroenterology & Hepatology at the Faculty of Medicine, the Hebrew University and Head of the Institute of Gastroenterology and Liver Disease at Hadassah, Jerusalem, Israel. After completing his medical training at the Hebrew University and Hadassah, he completed his residency in Gastroenterology/Hepatology at the Tel Aviv Sourasky Medical center followed by two years of fellowship in New York, combining research at Albert Einstein College of Medicine and advanced clinical fellowship at the Liver Division, Mount Sinai Medical Center. Dr. Oren established the Liver Unit in the Tel Aviv Sourasky Medical Center (2000) where he also served as Chief of Medicine (2008-2010). Dr. Oren published over the years in the fields of liver fibrosis, thyroid hormone effect on liver diseases and hepatocyte transplantation. In recent years his main research interests are in the field of non-alcoholic fatty liver disease (NAFLD) –epidemiology, risk factors, diagnosis and treatment. He had published several papers in the field and he is involved with clinical studies running in the field.
Mr. Tonelli joined Galmed in March, 2015, bringing 24 years of progressive experience in clinical development, operations and regulatory affairs. From 2005-2014, he planned and managed diabetes trials at MannKind Corporation, culminating in FDA approval of Afrezza® Inhalable Insulin. Prior to MannKind he held leadership positions in clinical development and project management at Innapharma. He began his career in regulatory affairs in the Medical Research Division of American Cyanamid (Lederle Labs). Mr. Tonelli holds a Bachelor of Science degree from Rutgers University.
Mr. Stenzler joined Galmed in June 2014 and serves as the Company’s Chief Financial Officer since February 2017. Mr. Stenzler brings Galmed six years of financial management experience as an accountant at the real estate department at Ernst & Young LLP, where he was involved in financing, taxes, auditing, advising and accounting of public and private companies, both domestic and international. Mr. Stenzler is a certified CPA and holds an MBA in Finance from Recanati Business School at Tel Aviv University, and a BA in Economics and Accounting from Ben-Gurion University of the Negev.